{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:53:52Z","timestamp":1648796032502},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CE"],"DOI":"10.2147\/ce.s7452","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:35:07Z","timestamp":1467246907000},"page":"0-0","source":"Crossref","is-referenced-by-count":0,"title":["Bortezomib: the evidence of its clinical impact in multiple myeloma"],"prefix":"10.2147","volume":"Volume 1-Issues 3 & 4","author":[{"family":"Core Journal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2006,6]]},"container-title":["Core Evidence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=4874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T21:53:28Z","timestamp":1477864408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/bortezomib-the-evidence-of-its-clinical-impact-in-multiple-myeloma-peer-reviewed-article-CE"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ce.s7452","relation":{},"ISSN":["1555-175X"],"issn-type":[{"value":"1555-175X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}